Exelixis, Inc. (EXEL) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Exelixis reported revenue of $2.32B, up 7.0% from $2.17B the year before. Net income was $782.6M (a 33.7% net margin), or $2.78 per diluted share. Gross margin was 96.4% and operating margin was 37.6%. Operating activities generated $884.3M of cash, leaving $875.8M of free cash flow. At fiscal year end, Exelixis held $2.84B in total assets against $683.1M in total liabilities, including $482.5M of cash and equivalents.
Open the full interactive Exelixis financials → Quarterly statements, key ratios, valuation history and price charts.
Exelixis Key Stats
| Share Price | $59.51 |
|---|---|
| Market Cap | $15.45B |
| P/E Ratio | 21.4 |
| Revenue YoY Growth | +7.0% |
| 52-Week Range | $34.54 – $59.86 |
| Shares Outstanding | 250.8 million (basic, 2026 Q2) |
Exelixis Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $987.5M | $1.43B | $1.61B | $1.83B | $2.17B | $2.32B |
| Cost of Goods Sold | $36.3M | $52.9M | $57.9M | $72.5M | $76.2M | $83.7M |
| Gross Profit | $951.3M | $1.38B | $1.55B | $1.76B | $2.09B | $2.24B |
| Operating Income | $110.1M | $286.7M | $201.5M | $170.9M | $604.6M | $872.2M |
| Pre-Tax Income | $130.8M | $294.2M | $234.4M | $257.5M | $681.6M | $941.2M |
| Income Tax | $19.1M | $63.1M | $52.1M | $49.8M | $160.4M | $158.6M |
| Net Income | $111.8M | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| Diluted EPS | $0.35 | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
Exelixis Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $597.8M | $598.7M | $610.8M | $628.7M |
| Net Income | $193.6M | $244.5M | $210.5M | $212.1M |
| Diluted EPS | $0.69 | $0.87 | $0.79 | $0.82 |
Exelixis Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $319.2M | $647.2M | $501.2M | $263.0M | $217.4M | $482.5M |
| Current Assets | $1.45B | $1.83B | $1.62B | $1.32B | $1.47B | $1.44B |
| Total Assets | $2.14B | $2.62B | $3.07B | $2.94B | $2.95B | $2.84B |
| Current Liabilities | $204.7M | $337.6M | $324.4M | $394.3M | $403.8M | $405.6M |
| Total Liabilities | $258.2M | $405.6M | $583.1M | $678.4M | $703.5M | $683.1M |
| Shareholders' Equity | $1.88B | $2.21B | $2.49B | $2.26B | $2.24B | $2.16B |
Exelixis Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $209.0M | $400.8M | $362.6M | $333.3M | $700.0M | $884.3M |
| Cash From Investing | -$131.2M | -$42.9M | -$524.4M | -$27.0M | -$116.8M | $350.4M |
| Cash From Financing | -$25.1M | -$14.8M | $586,000 | -$546.1M | -$628.8M | -$969.6M |
| Free Cash Flow | $178.6M | $336.6M | $334.9M | $292.9M | $671.5M | $875.8M |
Figures from Exelixis' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Exelixis financials page for every line item.
Exelixis Company Profile
| Ticker | EXEL |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Alameda, California |
| Incorporated in | Delaware |
| Fiscal Year End | January 1 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000939767 |
Frequently Asked Questions
What was Exelixis' revenue in fiscal 2025?
Exelixis (EXEL) reported revenue of $2.32B for fiscal 2025.
What is Exelixis' annual revenue history?
Exelixis' annual revenue by fiscal year: 2020: $987.5M; 2021: $1.43B; 2022: $1.61B; 2023: $1.83B; 2024: $2.17B; 2025: $2.32B.
What was Exelixis' net income in fiscal 2025?
Exelixis reported net income of $782.6M for fiscal 2025.
What was Exelixis' earnings per share (EPS) in fiscal 2025?
Exelixis' diluted EPS was $2.78 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Exelixis generate in fiscal 2025?
Exelixis generated $875.8M of free cash flow in fiscal 2025.
What was Exelixis' revenue last quarter?
In its most recent reported quarter (2026 Q2), Exelixis reported revenue of $628.7M.
How many shares of Exelixis are outstanding?
Exelixis reported a weighted average of 250.8 million basic shares outstanding in 2026 Q2.
What is Exelixis' market cap?
Based on its latest closing price, Exelixis (EXEL) has a market capitalization of about $15.45B.
When does Exelixis' fiscal year end?
Exelixis' fiscal year end, as registered with the SEC, is January 1.
Where is Exelixis headquartered?
Exelixis lists its business address in Alameda, California in its SEC filings.
Exelixis Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →